Mesoblast Limited is an Australian regenerative medicine company. It seeks to provide treatments for inflammatory ailments, cardiovascular disease and back pain. The company is led by Silviu Itescu, who founded the company in 2004. In Mesoblast's annual report from August 2010, the company first announced positive results of preclinical trials showing radiographic and pathologic disc regeneration with MPC-06-ID. Mesoblast said they were in the process of completing an Investigational New Drug (IND) submission to the United States FDA to commence Phase 2 clinical trials. In December 2010, Mesoblast entered an agreement with US-based Cephalon to develop and commercialize novel adult Mesenchymal Precursor Stem Cell (MPC) therapeutics for degenerative conditions of the cardiovascular and central nervous systems. More information...
According to PR-model, mesoblast.com is ranked 1,207,914th in multilingual Wikipedia, in particular this website is ranked 676,073rd in English Wikipedia.
The website is placed before pedagogie-medicale.org and after leabharmor.net in the BestRef global ranking of the most important sources of Wikipedia.
